Swiss City Draws Positive Results After Three Years Of Controlled Cannabis Sales
-
Deutsch
de
Basel-Stadt zieht nach drei Jahren Cannabis-Abgabe positive Bilanz
Original
Read more: Basel-Stadt zieht nach drei Jahren Cannabis-Abgabe positive B
Thanks to the Weed Care pilot project, the inhalation of smoke from joints containing tobacco has fallen significantly, the cantonal health department said on Thursday. Health risks have been reduced and consumption has not increased.
The introduction last autumn of non-smoked cannabis products – namely vaporisers and oils – into the controlled sales scheme has been a success: they now account for nearly a fifth of consumption, without total consumption having increased, the health department added.
The review of the past year also confirms the observations made a year ago regarding users' mental health. Symptoms of depression, anxiety and psychosis have decreased. The same applies to the consumption of alcohol and other psychoactive substances among participants in the Basel pilot project, which was launched in January 2023 and extended until January 2027.
+ Basel cannabis study reports improvements in smokers' mental health
Legalisation a genuine needThese positive interim results highlight the need to regulate the sale and consumption of cannabis through legislation, said Regine Steinauer, head of addiction services at the Basel-City Health Department.
More More High times in Basel: Swiss city experiments with recreational cannabisThis content was published on Nov 1, 2023 Switzerland has launched legal cannabis experiments in cities this year to assess the benefits of regulating the supply of the recreational drug.
Read more: High times in Basel: Swiss city experiments with recreational can
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.

Comments
No comment